FDA Approves Large Studies of Ecstasy to Treat PTSD
Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.
Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.
An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.
Click here to Read the full article: FDA Approves Large Studies of Ecstasy to Treat PTSD
Share this entry
- David Yorio, DO is Appointed to the American Health Council’s Board of Physicians July 20, 2018
- Jeri D. Graham, OD is Selected to the American Health Council’s Board of Physicians July 19, 2018
- American Health Council Names Deborah Barnes to MSW, LCSW, BCD to Industry Board July 16, 2018
- Michael Auer, PT, DPT, C/NDT, is Selected to the American Health Council’s Physical Therapy Board July 13, 2018
- The American Health Council Appoints Rosemary Royce, ADN, FNP to its Nursing Board July 11, 2018
- The American Health Council Welcomes Daniel Lichtstein, MD to Board of Physicians July 9, 2018